X
Xiaomei Ren
Researcher at Jinan University
Publications - 74
Citations - 2178
Xiaomei Ren is an academic researcher from Jinan University. The author has contributed to research in topics: Kinase & Chemistry. The author has an hindex of 22, co-authored 64 publications receiving 1678 citations. Previous affiliations of Xiaomei Ren include Chinese Ministry of Education & Sun Yat-sen University.
Papers
More filters
Journal ArticleDOI
Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway
Xiaomei Ren,Lei Duan,Qiang He,Zhang Zhang,Yi Zhou,Donghai Wu,Jingxuan Pan,Duanqing Pei,Ke Ding +8 more
TL;DR: Niclosamide, an FDA-approved anthelmintic drug, is identified as a new small-molecule inhibitor of the STAT3 signaling pathway and consequently induced cell growth inhibition, apoptosis, and cell cycle arrest of cancer cells with constitutively active STAT3.
Journal ArticleDOI
Surface ozone trend details and interpretations in Beijing, 2001–2006
TL;DR: In this article, the authors analyzed data on ozone and nitrogen oxide levels obtained at six urban sites in Beijing between the months of July and September, and investigated average trends and interpretations over the 2001-2006 period.
Journal ArticleDOI
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma
Chiara Ambrogio,Gonzalo Gómez-López,Mattia Falcone,August Vidal,Ernest Nadal,Nicola Crosetto,Rafael B Blasco,Pablo J. Fernandez-Marcos,Montserrat Sanchez-Cespedes,Xiaomei Ren,Zhen Wang,Ke Ding,Manuel Hidalgo,Manuel Serrano,Alberto Villanueva,David Santamaría,Mariano Barbacid +16 more
TL;DR: The data indicate that the combined inhibition of DDR1 and Notch signaling could be an effective targeted therapy for patients with KRAS-mutant lung adenocarcinoma.
Journal ArticleDOI
Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.
Mingshan Gao,Lei Duan,Jinfeng Luo,Lianwen Zhang,Xiaoyun Lu,Yan Zhang,Zhang Zhang,Zhengchao Tu,Yong Xu,Xiaomei Ren,Ke Ding +10 more
TL;DR: A series of 3-(2-(pyrazolo[1,5-a]pyrimidin-6-yl) ethynyl)benzamides that are selective and orally bioavailable DDR1 inhibitors are discovered that inhibited the enzymatic activity of DDR1 and strongly suppressed cancer cell invasion, adhesion, and tumorigenicity.
Journal ArticleDOI
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
Xiaomei Ren,Xiaofen Pan,Zhang Zhang,Deping Wang,Deping Wang,Xiaoyun Lu,Yupeng Li,Yupeng Li,Donghai Wen,Huoyou Long,Jinfeng Luo,Yubing Feng,Xiaoxi Zhuang,Fengxiang Zhang,Liu Jianqi,Fang Leng,Xingfen Lang,Yang Bai,Miaoqin She,Zhengchao Tu,Jingxuan Pan,Ke Ding +21 more
TL;DR: GZD824 represents a promising lead candidate for development of Bcr-Abl inhibitors to overcome acquired imatinib resistance and significantly improved the survival of mice bearing an allograft leukemia model with Ba/F3 cells harboring Bcr -Abl(T315I).